SCHEMBL4100162

SCHEMBL4100162

O=C1CC2CC(O)CC2C1

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13774695 1.00 MEN1 (0.35) MEN1KMT2A
SCHEMBL16666800 1.00 MEN1 (0.35) MEN1KMT2A
SCHEMBL13774728 1.00 MEN1 (0.35) MEN1KMT2A
SCHEMBL16512582 0.85 MEN1 (0.31) MEN1KMT2A
SCHEMBL12777784 0.81
SCHEMBL1003675 0.81
SCHEMBL570266 0.75
SCHEMBL8526654 0.75
SCHEMBL8526655 0.75
SCHEMBL18213710 0.75 SHBG (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176847-A1 Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2009-07-09 US claimed
EP-2006284-A1 DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) 2008-12-24 EP claimed
US-20030158208-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC. 2003-08-21 US claimed
US-20020049209-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC. 2002-04-25 US claimed
US-6372762-B1 HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS PFIZER INC. 2002-04-16 US claimed
EP-1177792-A2 Dopamine D4 Ligands for the treatment of novelty-seeking disorders Pfizer Products Inc. (US) 2002-02-06 EP claimed
EP-0953567-A2 Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity Pfizer Products Inc. (US) 1999-11-03 EP claimed
EP-4653428-A1 PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TRIAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2025-11-26 EP disclosed
US-20240317725-A1 LPA1 SMALL MOLECULE ANTAGONIST TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) 2024-09-26 US disclosed
EP-4375277-A1 LPA1 SMALL MOLECULE ANTAGONIST Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2024-05-29 EP disclosed
CN-117460721-A LPA1 small molecule antagonist 上海拓界生物医药科技有限公司 2024-01-26 CN disclosed
EP-2865666-B1 HEXAHYDROPENTALENO DERIVATIVES, PREPARATION METHOD AND USE IN MEDICINE THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2017-05-31 EP disclosed
US-20090176847-A1 Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2009-07-09 US disclosed
US-20030158208-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC. 2003-08-21 US disclosed
US-6548502-B2 Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives PFIZER INC 2003-04-15 US disclosed
US-20020049209-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders PFIZER INC. 2002-04-25 US disclosed
US-6372762-B1 HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS PFIZER INC. 2002-04-16 US disclosed
EP-1177792-A2 Dopamine D4 Ligands for the treatment of novelty-seeking disorders Pfizer Products Inc. (US) 2002-02-06 EP disclosed
EP-0953567-A2 Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity Pfizer Products Inc. (US) 1999-11-03 EP disclosed
US-4307112-A 9-Deoxy-9A-methylene isosteres of PGI2 and process for their preparation FARMITALIA CARLO ERBA S.P.A. (IT) 1981-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049209-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders SLC6A3, DRD4, DRD2 MEN1 4261/4885KMT2A 1418/4885
US-20090176847-A1 Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof DPP4, DPP7, DPP8 MEN1 1501/4885KMT2A 3316/4885
US-20030158208-A1 Dopamine D4 ligands for the treatment of novelty-seeking disorders SLC6A3, DRD4, DRD2 MEN1 4261/4885KMT2A 1418/4885
US-20240317725-A1 LPA1 SMALL MOLECULE ANTAGONIST LPAR1, LPAR2, LPAR4 MEN1 1365/4885KMT2A 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.